| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/04/2022 | 110.53% | HC Wainwright & Co. | $3 → $4 | Maintains | Buy |
| 07/18/2022 | 189.47% | Oppenheimer | → $5.5 | Assumes | → Outperform |
| 07/01/2020 | 163.16% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 06/23/2020 | 57.89% | Maxim Group | → $3 | Initiates Coverage On | → Buy |
| 01/21/2020 | 426.32% | Roth Capital | → $10 | Assumes | → Buy |
| 09/13/2019 | 478.95% | Roth Capital | → $11 | Initiates Coverage On | → Buy |
| 07/30/2019 | 215.79% | Brookline Capital | → $6 | Initiates Coverage On | → Buy |
| 05/02/2019 | 110.53% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
Cellectar Biosciences Questions & Answers
The latest price target for Cellectar Biosciences (NASDAQ: CLRB) was reported by HC Wainwright & Co. on November 4, 2022. The analyst firm set a price target for $4.00 expecting CLRB to rise to within 12 months (a possible 110.53% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Cellectar Biosciences (NASDAQ: CLRB) was provided by HC Wainwright & Co., and Cellectar Biosciences maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectar Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectar Biosciences was filed on November 4, 2022 so you should expect the next rating to be made available sometime around November 4, 2023.
While ratings are subjective and will change, the latest Cellectar Biosciences (CLRB) rating was a maintained with a price target of $3.00 to $4.00. The current price Cellectar Biosciences (CLRB) is trading at is $1.90, which is out of the analyst's predicted range.